TY - JOUR
T1 - Advances in molecular imaging for the diagnosis of dementia
AU - Okamura, Nobuyuki
AU - Fodero-Tavoletti, Michelle T.
AU - Kudo, Yukitsuka
AU - Rowe, Christopher C.
AU - Furumoto, Shozo
AU - Arai, Hiroyuki
AU - Masters, Colin L.
AU - Yanai, Kazuhiko
AU - Villemagne, Victor L.
N1 - Funding Information:
This study was partially supported by the Special Coordination Funds for Promoting Science and Technology, the Program for the Promotion of Fundamental Studies in Health Science by the National Institute of Biomedical Innovation, the Industrial Technology Research Grant Program from the New Energy and Industrial Technology Development Organization (NEDO) of Japan, the Health and Labor Sciences Research Grants for Translational Research from the Japanese Ministry of Health, Labor, and Welfare, a JST grant on research and education in molecular imaging, and NHMRC project grant 509166.
PY - 2009/11
Y1 - 2009/11
N2 - Background: There is an urgent need for early diagnosis and treatment of dementia to ease caregiver burden and medical costs associated with the increasing number of affected patients. Molecular imaging with target-specific ligands is contributing to the early diagnosis of dementia and the evaluation of anti-dementia therapy. Objective: This article reviews recent advances in the molecular imaging field applied to dementia. To illustrate the utility of molecular imaging in the clinical management of dementia, results from recently published papers using new imaging probes are compared with those from conventional imaging strategies. Conclusion: The recent development of β-sheet binding agents including FDDNP, PIB, SB-13, BF-227 and BAY94-9172 enables the non-invasive detection of amyloid deposition in the brain. These agents would be useful for the early and accurate diagnosis of Alzheimer's disease, patient selection for disease-modifying therapeutic trials and monitoring the effect of anti-amyloid therapy. Also, monitoring neurotransmitter function contributes to the differential diagnosis of dementia and refinement of treatment protocols. New targets for molecular imaging are focusing on protein misfolding diseases associated with the neurotoxic deposition of aggregated tau, α-synuclein and prion proteins.
AB - Background: There is an urgent need for early diagnosis and treatment of dementia to ease caregiver burden and medical costs associated with the increasing number of affected patients. Molecular imaging with target-specific ligands is contributing to the early diagnosis of dementia and the evaluation of anti-dementia therapy. Objective: This article reviews recent advances in the molecular imaging field applied to dementia. To illustrate the utility of molecular imaging in the clinical management of dementia, results from recently published papers using new imaging probes are compared with those from conventional imaging strategies. Conclusion: The recent development of β-sheet binding agents including FDDNP, PIB, SB-13, BF-227 and BAY94-9172 enables the non-invasive detection of amyloid deposition in the brain. These agents would be useful for the early and accurate diagnosis of Alzheimer's disease, patient selection for disease-modifying therapeutic trials and monitoring the effect of anti-amyloid therapy. Also, monitoring neurotransmitter function contributes to the differential diagnosis of dementia and refinement of treatment protocols. New targets for molecular imaging are focusing on protein misfolding diseases associated with the neurotoxic deposition of aggregated tau, α-synuclein and prion proteins.
KW - Acetylcholine
KW - Alzheimer's disease
KW - Amyloid-β protein
KW - Dementia
KW - Imaging
KW - Molecular imaging
KW - Near-infrared
KW - Positron emission tomography
KW - Prion
KW - Single photon emission computed tomography
KW - Tau
UR - http://www.scopus.com/inward/record.url?scp=77951810268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951810268&partnerID=8YFLogxK
U2 - 10.1517/17530050903133790
DO - 10.1517/17530050903133790
M3 - Review article
C2 - 23496052
AN - SCOPUS:77951810268
VL - 3
SP - 705
EP - 716
JO - Expert Opinion on Medical Diagnostics
JF - Expert Opinion on Medical Diagnostics
SN - 1753-0059
IS - 6
ER -